Uterine Sarcoma
16
2
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (16)
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma
A Prospective Validation Study of Radiomics in the Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
Radiomics-Based Non-Invasive MRI Differentiation of Uterine Sarcomas and Fibroids
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)
Construction of a Model for the Differential Diagnosis of SArcoma/myoma Based on the RAdiomics Features: Single-center Observational Study
UNDERSTANDING the RAREST GYNECOLOGICAL CANCERS: a MULTI -OMICS PLATFORM for IMPROVED PATIENTS MANAGEMENT
Vaccine Therapy in Treating Patients With Metastatic Cancer
Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids
Molecular Mechanism Study of Uterine Sarcoma
The Application of Real-Time Near-infrared Imaging in Gynecological Surgery
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors
The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas